• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hepatic-Metabolite-Based Intermittent Fasting Enables a Sustained Reduction in Insulin Resistance in Type 2 Diabetes and Metabolic Syndrome
Horm Metab Res DOI: 10.1055/a-1510-8896Insulin resistance is the hallmark of Type 2 Diabetes and is still an unmet medical need. Insulin resistance lies at the crossroads of non-alcoholic fatty liver disease, obesity, weight loss and exercise resistance, heart disease, stroke, depression, and brain health. Insulin resistance is purely nutrition related, with a typical molecular disease food intake pattern. The insulin resistant state is accessible by TyG as the appropriate surrogate marker, which is found to lead the personalized molecular hepatic nutrition system for highly efficient ins...
Source: Hormone and Metabolic Research - June 30, 2021 Category: Endocrinology Authors: Rohner, Markus Heiz, Robert Feldhaus, Simon Bornstein, Stefan R. Tags: Endocrine Care Source Type: research

Potential impact of gradual reduction of fat content in manufactured and out-of-home food on obesity in the United Kingdom: a modeling study
ConclusionsA modest fat reduction (particularly in SFA) in widely consumed foods would prevent obesity, type 2 diabetes, and cardiovascular disease.
Source: American Journal of Clinical Nutrition - May 8, 2021 Category: Nutrition Source Type: research

Role Of Glp-1 Analogs In The Management Of Diabetes And Its Secondary Complication
Mini Rev Med Chem. 2021 Apr 21. doi: 10.2174/1389557521666210422114909. Online ahead of print.ABSTRACTThe cardiovascular complications of type 2 diabetes mellitus (T2DM) include myocardial infarction, heart failure, peripheral vascular disease and, stroke and retinopathy, nephropathy and neuropathy are microvascular complications. While the newer therapies like glitazones or even dipeptidyl-peptidase-IV (DPP-IV) inhibitors increase the risk of therapy, the Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs), were reported as suitable alternates. The GLP-1RAs reduce the major adverse cardiovascular events (MACE), have anti...
Source: Mini Reviews in Medicinal Chemistry - April 23, 2021 Category: Chemistry Authors: Ponnurengam Malliappan Sivakumar B Premkumar Prabhawathi Veluchamy Pranav Kumar Prabhakar Source Type: research

BMI and BMI change following incident type 2 diabetes and risk of microvascular and macrovascular complications: the EPIC-Potsdam study
Conclusions/interpretationAmong people with incident type 2 diabetes, pre-diagnosis BMI was positively associated with microvascular complications, while a reduced risk was observed with weight loss when compared with stable weight. The relationships with macrovascular disease were less clear.Graphical abstract
Source: Diabetologia - March 8, 2021 Category: Endocrinology Source Type: research

Potential impact of gradual reduction of fat content in manufactured and out-of-home food on obesity in the United Kingdom: a modeling study
CONCLUSIONS: A modest fat reduction (particularly in SFA) in widely consumed foods would prevent obesity, type 2 diabetes, and cardiovascular disease.PMID:33677474 | DOI:10.1093/ajcn/nqaa396
Source: The American Journal of Clinical Nutrition - March 7, 2021 Category: Nutrition Authors: Roberta Alessandrini Feng J He Yuan Ma Vincenzo Scrutinio David S Wald Graham A MacGregor Source Type: research

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
Conclusion: SGLT2 inhibitors are novel antidiabetic medications with immense utility in the management of patients with T2DM. Furthermore, SGLT2 inhibitors have demonstrated to reduce the progression to advanced forms of kidney disease and its associated complications. These medications should be front and center in the management of patients with diabetic kidney disease with and without chronic kidney disease as they confer protection against cardiovascular/renal death and improve all-cause mortality. Future studies should evaluate the benefits and implications of early initiation of SGLT2 inhibitors, as well as the long-...
Source: International Journal of Nephrology and Renovascular Disease - November 7, 2020 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research

Pages: 1  2  3  4  5  6  7  8